A critical review of endpoints for non-cirrhotic NASH therapeutic trials

JOURNAL OF HEPATOLOGY

卷:68

Review

Ratziu, Vlad^1,2 

[1] Hosp Pitie Salpetriere, Inst Cardiometab & Nutr, Paris, France

[2] Sorbonne Univ, Univ Pierre & Marie Curie, Paris, France

关键词: Randomised controlled trials;    NASH;    Fibrosis;    Steatohepatitis;    Steatosis;    Magnetic resonance imaging;    Trial outcomes;   

DOI  :  10.1016/j.jhep.2017.12.001

来源: Elsevier

【 摘 要 】

Non-alcoholic steatohepatitis is a disease without a single, specific, diagnostic marker, hence multiple indicators are required to measure therapeutic efficacy. Moreover, drug candidates for non-alcoholic steatohepatitis target many distinct mechanisms that are believed to promote hepatic injury. Therefore, a wide range of endpoints must be reached, sequentially, as required by the drug development process. Some of these endpoints validate the mechanism of action, others are used to anticipate histological efficacy. Histological endpoints are still considered the best predictors of clinical outcome, but they can only be reliably tested in larger, late phase trials. Herein, we will review the rationale and clinical data supporting the use of specific endpoints at different stages of therapeutic trials. We will also discuss the validity and limitations of current phase IIb histological endpoints, particularly a one stage reduction in fibrosis, for their ability to predict progression to cirrhosis, which is the ultimate outcome measure in therapeutic trials. (C) 2017 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.

【 授权许可】

Free